In the last trading session, 1.15 million shares of the Autolus Therapeutics plc ADR (NASDAQ:AUTL) were traded, and its beta was 1.99. Most recently the company’s share price was $4.56, and it changed around $0.04 or 0.88% from the last close, which brings the market valuation of the company to $793.90M. AUTL currently trades at a discount to its 52-week high of $7.45, offering almost -63.38% off that amount. The share price’s 52-week low was $1.61, which indicates that the current value has risen by an impressive 64.69% since then. We note from Autolus Therapeutics plc ADR’s average daily trading volume that its 3-month average coming to 1.54 million.
Autolus Therapeutics plc ADR stock received a consensus recommendation rating of Overweight, based on a mean score of 1.36. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended AUTL as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Autolus Therapeutics plc ADR is expected to report earnings per share of $ALTL for the current quarter.
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Instantly AUTL has showed a green trend with a performance of 0.88% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -29.19% year-to-date, but still down -6.94% over the last five days. On the other hand, Autolus Therapeutics plc ADR (NASDAQ:AUTL) is -27.04% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $11, which translates to bulls needing to increase their stock price by 58.55% from its current value. Analyst projections state that AUTL is forecast to be at a low of $11 and a high of $11.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
Autolus Therapeutics plc ADR share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 82.40 percent over the past six months and at a 40.83% annual growth rate that is well above the industry average of 13.30%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 3.32%.
AUTL Dividends
Autolus Therapeutics plc ADR’s next quarterly earnings report is expected to be released in May.
